A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.

Yasue Tsuchida,Sachiko Ohde,Ryota Nakamura,Yoko Kanada,Sakiko Miura,Masafumi Takimoto,Seigo Nakamura,Naoki Kanomata,Hideko Yamauchi,Naoki Hayashi

A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.

2021

Yasue Tsuchida
Sachiko Ohde
Ryota Nakamura
Yoko Kanada
Sakiko Miura
Masafumi Takimoto
Seigo Nakamura
Naoki Kanomata
Hideko Yamauchi
Naoki Hayashi

532Background: In the prospective TAILORx and RxPONDER trials, the 21-gene Recurrence Score (RS) showed endocrine therapy alone was non-inferior to chemo-endocrine therapy in the analysis of invasi...

Keywords:

Medicine
recurrence score
Oncology
Internal medicine
Breast cancer
21 gene recurrence score
Hormone receptor
recurrence risk
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations